Search for a trial

Reducing costs of surveillance of patients with non-muscle invasive bladder cancer.

1) To prove that it is possible to safely reduce the number of invasive cystoscopies during follow-up (FUP) of patients with NMIBC with a low/intermediate risk of recurrence or progression. 2) To prove that addition of urine tests to the follow-up…

Single Blind Randomized Phase III Trial to Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

- Primary study objective: To demonstrate the superiority of the ablative microboost dose schedule regarding 5-year biochemical no evidence of disease rate compared to the current standard of care.- Secondary study objectives: Establish and compare…

Ligasure versus conventional surgery for inguinofemoral lymphadenectomy in vulvar cancer patients; MAMBO-IC

Our primary objective is to assess the differences in the incidence of short term complications (wound infection, wound breakdown and lymphocele) after IFL using LigaSure versus the conventional method. Furthermore, we will assess the differences in…

Randomised Controlled Study on the Effects of Imiquimod, a TLR 7 Activating Agent, on the HPV16-Specific Immune Response Following HPV16 E6/E7 Synthetic Long Peptides Vaccination in Women with HPV16 Positive High Grade Vulvar/Vaginal Intraepithelial Neoplasia.

Primary objective:To compare the immunological response to vaccination with HPV16 E6 and E7 synthetic long peptides with concomitant application of imiquimod at the vaccination site with vaccination without the concomitant application of imiquimod.…

A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxoterere* (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA.

To evaluate and compare progression free survival (PSA) between the two treatment arms.

The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate risk prostate carcinoma (NEO-ONE)

To assess the effects of 3-month NHT on the 3-year course of PSA and testosterone in patients treated with BT for low-intermediate risk clinically localized prostate carcinoma. In addition, we would like to assess the effects of 3-month NHT on…

Clinical and immunological effects of imiquimod and HPV-vaccination compared to imiquimod alone in female patients with Usual type VIN: proof of principle.

Primary objectives: (1) Evaluation of the efficacy of vaccination against HPV 16, 18, 6 and 11 followed by local applications of imiquimod 5% cream compared to treatment with imiquimod alone for usual type VIN, (2) evaluation of the systemic and…

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer.

To determine if denosumab is non-inferior to zoledronic acid (Zometa) with respect to the first on-study occurrence of a skeletal-related event (SRE) in men with hormone-refractory prostate cancer and bone metastases.

A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients

To Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients compared to placebo.

A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer

Evaluate the efficacy and safety of treatment with CNTO 95 in combination with docetaxel and prednisone compared with docetaxel and prednisone without CNTO 95 in subjects with metastatic HRPC.

Phase II multi-centric, randomised, open-label, parallel-group study to assess the non-inferiority of Pamorelin® 11,25 mg SC injected versus Pamorelin® 11,25 mg IM injected in patients suffering from advanced prostate cancer

Primary Study ObjectiveTo assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via registered intramuscular (IM) injection…

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer

Primary Efficacy Objectives:To ascertain whether the overall survival of subjects randomized to Arm V+G (PROSTVAC-V/F plus GM-CSF) or to Arm V (PROSTVAC-V/F) is superior to that from subjects randomized to Arm P (placebo control).Secondary Efficacy…

A double-blind, randomised, placebo-controlled, multi-center study to evaluate effects of estetrol on testosterone suppression and quality of life in prostate cancer patients
treated with an LHRH agonist

The purpose of this study is to evaluate the effect of E4 on the efficacy and health related quality of life of prostate cancer patients on LHRH agonist treatment.Primary objectives:• To assess the additional suppressive effects of E4 on total T and…

Prostate cancer and diet - a randomized controlled trial on the effect of a dietary intervention on the quality of life of men and serum nutrient levels in their blood.

Primary objective: to improve participants* quality of life, as measured by the SF-12 general health domain, by actively engaging in a prostate cancer diet. Secondary objectives: - To improve participants* feeling of being in control of their…

SUPERvised three-month exercise program in MEN with Prostate cAncer Receiving androgen-deprivaTioN thERapy

To examine the impact of a supervised training program on disease-related quality of life and physical fitness in patient with advanced prostate cancer compared to usual care.